This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by a Postdoctoral Health Economics and Outcomes Research Fellowship awarded to one of the authors from Genentech.
Reference
Neuberger EE, et al. Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome. PharmacoEconomics : 26 Jul 2020. Available from: URL: http://doi.org/10.1007/s40273-020-00945-z
Rights and permissions
About this article
Cite this article
Cannabidiol in Lennox-Gastaut syndrome: modest benefits at high cost. PharmacoEcon Outcomes News 859, 7 (2020). https://doi.org/10.1007/s40274-020-7016-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7016-x